Ozempic face: what is it and how can you prevent a gaunt appearance when taking GLP-1 medication?

Short answer: ‘Ozempic face’ is the colloquial term for a gaunt-looking face following rapid weight loss with GLP-1 medication. It is caused by a loss of facial fat and is not a recognised side effect, but rather an aesthetic effect that can be minimised by following a gradual weight-gain programme.

‘Ozempic face’ is the colloquial term for a sunken, aged-looking face following rapid weight loss with GLP-1 medicines such as Ozempic, Wegovy, Mounjaro and Saxenda. Holler cheeks, deeper wrinkles around the mouth and a loss of youthful volume: these are recognisable signs that many users see appearing online. But what actually happens to your face during weight loss, why does it affect some people and not others, and what can you do about it yourself? This blog provides an honest, medically substantiated answer.

What exactly is the ‘Ozempic face’?

The ‘Ozempic face’ is not an official medical term or a recognised side effect of semaglutide, but a collective term that has emerged on social media. The term describes facial changes resulting from significant fat loss in the face: sunken cheeks, deeper wrinkles around the nose and mouth, and a loss of the youthful volume that makes a face look full and relaxed.

A recent review of the literature describes that these changes are linked to a loss of facial volume and thinning of the skin resulting from a decline in collagen, particularly following rapid and significant weight loss. The term does not originate from clinical research, but the underlying mechanisms are certainly described in the scientific literature. This distinction is important: the phenomenon is real, whilst the term is colloquial.

What causes a sunken face following weight loss?

A sunken face occurs because the face contains a relatively large amount of subcutaneous fat, particularly in the cheeks and around the eyes. With rapid weight loss, this fat disappears, whilst the skin does not always contract at the same rate.

Studies of tissue changes following weight loss show that the skin’s elasticity is a decisive factor: the less elastic the skin is, the greater the risk of visible sagging following a loss of volume. This is particularly true for older users, as skin elasticity and collagen production naturally decline with age. It is important to note that this is not an effect unique to GLP-1 medicines, but a well-known consequence of rapid weight loss in general. Doctors observe the same pattern following gastric bypass surgery or extreme dieting.

Does this apply to all GLP-1 medicines: Ozempic, Wegovy, Mounjaro and Saxenda?

Yes, the risk depends on the extent and rate of weight loss, not on the specific molecule. Semaglutide, the active ingredient in Ozempic (semaglutide), Wegovy and Rybelsus; tirzepatide in Mounjaro (tirzepatide) and Zepbound; and liraglutide in Saxenda (liraglutide) can all cause this potential effect in the event of significant weight loss.

A network meta-analysis of body composition shows that tirzepatide, on average, results in slightly greater weight loss than semaglutide, which could theoretically have a greater effect on facial volume during rapid weight loss. Liraglutide, which has a more gradual onset of action due to its daily dosing, generally shows a similar pattern, which correlates with overall weight loss. It is therefore not a question of which medicine is used, but of how much and how quickly one loses weight.

Who is most at risk of developing an ‘Ozempic face’?

People who lose weight quickly and significantly – for example, more than one per cent of their body weight per week – are at the greatest risk of visible loss of facial volume. Older users naturally have less skin elasticity and collagen, which means the skin cannot keep up as the fat disappears.

Smoking accelerates skin ageing and further reduces elasticity, which increases the risk even further. People who naturally have little facial fat also notice volume loss earlier, as they have less of a ‘buffer’. According to Farmacotherapeutisch Kompas, a gradual dose escalation is specifically designed to regulate the pace of weight loss, which indirectly also limits this risk.

How can you prevent or minimise a sunken face?

A gradual dose titration is the first and most important measure, and this is precisely what the standard titration schedule for GLP-1 medicines is already designed to achieve. A slower start gives your body and skin more time to adapt to the changing volume.

In addition, adequate protein intake whilst using GLP-1 is important, combined with strength training to maintain muscle mass, including in the jaw and neck area. Research into muscle mass loss during GLP-1 treatment indicates that targeted mitigation strategies, such as protein intake, can limit the loss of lean body mass. A study on strength training during incretin-based treatment confirms that resistance exercises have a beneficial effect on changes in body composition. Adequate hydration and basic skincare with SPF and, where appropriate, retinoids can support skin quality, although this is general advice with no guaranteed effect on facial volume. Always discuss any concerns about the rate of your weight loss with your treating doctor or coach.

Can a sunken face be reversed?

Partially: Facial volume may partially return as soon as your weight stabilises, but the skin’s elasticity is restored considerably more slowly than fat tissue. Once your weight stabilises, the body gradually rebuilds some fat, including in the face, which can compensate for some of the lost volume.

For people who, after stabilisation, are still bothered by sagging skin, there are cosmetic options such as dermal fillers. This is mentioned here for information purposes only: Goodweigh does not recommend this and does not offer it as part of our own services. Such a treatment is an individual, cosmetic choice which you should discuss with a qualified specialist, independently of your GLP-1 treatment.

The ‘Ozempic face’ in perspective

A sunken face is a possible aesthetic effect of rapid weight loss, not a dangerous side effect. It is not a reason to stop an effective treatment, but a reason to consciously monitor the pace of your weight loss. With a gradual weight loss programme, adequate protein intake and coaching to monitor the pace of your weight loss, the risk can be significantly reduced. Would you like to know what a realistic weight loss means for you? Read more about how much weight you can lose with Ozempic, and book your initial consultation today to receive personalised guidance.